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The pathogenesis of diabetic retinopathy (DR) remains unclear but hyperglycemia is an established risk factor. Endothelial
dysfunction and changes in Ca2+ signaling have been shown to precede the onset of DR. We recently demonstrated that high
extracellular glucose activates the Ca2+/calcineurin-dependent transcription factor NFAT in cerebral arteries and aorta, promoting
the expression of inflammatory markers. Here we show, using confocal immunofluorescence, that NFAT is expressed in the
endothelium of retinal microvessels and is readily activated by high glucose. This was inhibited by the NFAT blocker A-285222
as well as by the ectonucleotidase apyrase, suggesting a mechanism involving the release of extracellular nucleotides. Acute
hyperglycemia induced by an IP-GTT (intraperitoneal glucose tolerance test) resulted in increased NFATc3 nuclear accumulation
and NFAT-dependent transcriptional activity in retinal vessels of NFAT-luciferase reporter mice. In both Akita (Ins2+/−) and
streptozotocin- (STZ-) induced diabetic mice, NFAT transcriptional activity was elevated in retinal vessels. In vivo inhibition
of NFAT with A-285222 decreased the expression of OPN and ICAM-1 mRNA in retinal vessels, prevented a diabetes driven
downregulation of anti-inflammatory IL-10 in retina, and abrogated the increased vascular permeability observed in diabetic mice.
Results identify NFAT signaling as a putative target for treatment of microvascular complications in diabetes.
1. Introduction
Diabetic retinopathy (DR) is still one of the leading causes
of vision loss worldwide. Even though the underlying patho-
genesis is not clear, hyperglycemia is an important risk
factor [1]. We have recently demonstrated that modest eleva-
tions of extracellular glucose activate the Ca2+/calcineurin-
dependent transcription factor NFAT (nuclear factor of acti-
vated T cells) in smoothmuscle cells of conduit and resistance
arteries [2, 3]. The effect of glucose involved the local release
of extracellular nucleotides, such as ATP and UTP, acting
on P2Y receptors, leading to increased intracellular Ca2+
([Ca2+]i) and subsequent activation of calcineurin and NFAT
[2]. ATP and UTP are vasoactive signals able to increase
[Ca2+]i in the retina, via stimulation of purinergic receptors
including P2Y4 [4]. Also, high glucose has been shown to
increase extracellular ATP in rat retinal cell cultures [5].
Therefore, we hypothesize that hyperglycemia may activate
NFAT in retinal microvessels.
Inflammation and endothelial activation are important
early steps in the development of DR, leading to leukosta-
sis, platelet activation, and upregulation of inflammatory
cytokines [6]. The NFAT family (NFATc1–c4) plays a central
role in the production of cytokines in immune cells and
in the regulation of T-cell proliferation. We and others
have shown that in conduit and resistance arteries and in
cultured vascular cells NFAT regulates the expression of
inflammatory genes, such as IL-6, allograft inflammatory
factor 1 (AIF-1), tissue factor (TF), cyclooxygenase 2 (Cox-2),
and osteopontin (OPN) [3, 7–9]. Expression of endothelial
activation markers, such as VCAM-1 and E-selectin, is also
dependent on NFAT signaling in cultured smooth muscle
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and endothelial cells, respectively [10, 11]. More recently, we
showed that in vivo inhibition of NFAT signaling reduces
ICAM-1 mRNA expression in the aortas of diabetic Apoe−/−
mice [9], a leukocyte adhesion molecule that is elevated in
retinal vessels from diabetic mice and patients [6, 12].
Another early feature of DR is the breakdown of the
blood-retinal barrier (BRB) [13], which results in vascular
leakage and development of retinal edema. Earlier investiga-
tions focused on vascular endothelial growth factor (VEGF),
shown to induce rapid phosphorylation of tight junction
proteins and increased retinal permeability [14]. However,
recent in vivo kinetic data show that the retinal barrier
function is compromised before VEGF levels are increased
and use of a neutralizing anti-VEGF antibody is not effective
at reducing permeability at early stages of diabetes (8 weeks)
[15]. In the context of angiogenesis [16, 17], VEGF appears to
be an upstream activator of NFAT, but both VEGF and its
receptor VEGFR2 are also downstream targets of NFAT in
endothelial cells [18, 19]. Hence, a role of NFAT in the early
changes of DR cannot be ruled out.
Here, we investigated the effects of high glucose and dia-
betes on NFAT activation in a streptozotocin (STZ) model of
diabetes and in hyperglycemic Akita (Ins2+/−) mice. We also
explored the effects of in vivo NFAT-signaling inhibition on
the expression of inflammatory mediators, endothelial adhe-
sion molecules, and vascular permeability in diabetic mice.
2. Research Design and Methods
2.1. Animals. All animal protocols in this study were
reviewed and approved by Institutional Animal Care and Use
Committees, University of New Mexico, School of Medicine
and Lund University, Sweden. The following mice strains
(number of animals per strain indicated) were bred in our
animal facilities: FVBN 9x-NFAT-luciferase reporter (NFAT-
luc [2, 7, 20]; 𝑁 = 133), Akita (Ins2+/−), and wild-
type (Ins2+/+) littermates (stock number 003548, C57Bl/6J
background, Jackson Laboratories, Maine, here referred to as
Akita and WT; 𝑁 = 31). We also generated Akita/NFAT-
luc mice and WT/NFAT-luc littermates (𝑁 = 43), which
were backcrossed at least four generations into the C57Bl/6J
background. Wild-type adult BALB/c (𝑁 = 76), C57Bl/6
(Taconic, Europe; 𝑁 = 12), and ApoE−/− (B6.129P2-
Apoetm1Unc/J; Charles River, Sulzfeld, Germany;𝑁 = 22)mice
were also used. Animals had free access to tap water and were
fed normal chow diet. Retinas, cerebral arteries, aortas, and
plasma were used. Both eyes were enucleated from all mice
included in this study; however, not always both eyes were
used (some were stored for future studies). If both eyes were
used, each eye was processed differently for the various types
of measurements detailed below. For in vivo experiments
using A-285222, the drug was administered intraperitoneally
(i.p.) once a day for the duration of the experiments, at 0.15–
0.29mg/kg body weight depending on the mouse strain and
based on previous studies [3]. A-285222 is a low molecular
weight (461 daltons), cell permeable organic compound
that inhibits all NFAT family members and was provided
by Abbott Laboratories (Abbott Park, IL). For experiments
involving collection of blood at termination,micewere anaes-
thetized by i.p. injection of 7.5mg ketamine hydrochloride
and 2.5mg xylazine per 100mg body weight and euthanized
by exsanguination through cardiac puncture. For all other
experiments, mice were euthanized by cervical dislocation or
pentobarbital injection (200mg/kg) followed by decapitation.
2.2. Isolation of Retinal Vessels. Eyes were enucleated and
retinas dissected in ice-cold Ca2+-free physiological saline
solution (PSS; in mmol/L: NaCl, 135; KCl, 5.9; MgCl
2
, 1.2;
Hepes, 11.6; glucose, 2.0; pH 7.4). Retinal vessels were isolated
from one eye as previously described [21]; the second eye
was used for measurements in whole retina (see below). A
total of 194 eyes were used for isolation of retinal vessels.
Vessel integrity after isolation was confirmed by staining
the vessel networks with smooth muscle 𝛼-actin antibody
and the fluorescent nucleic acid dye SYTOX green (1 : 3000,
Molecular Probes, Invitrogen, Paisley, UK). Intact retinal
endothelial and smooth muscle cells were visualized by
confocal microscopy as described below. Potential residual
levels of neuronal and glial contamination were assessed by
quantitative RT-PCR measuring Tau and GFAP expression,
respectively, using 18S as endogenous control.
2.3. RNA Isolation, Conventional RT-PCR, and Quantitative
Real Time PCR. Total RNAwas extracted fromwhole retinas,
isolated retinal vessels, and aortas from mice and from
human retinal microvessel endothelial cells (HRMVECs) as
previously described [3, 21]. HRMVECs (catalog number
ACBRI 181) were purchased from Cell Systems (Kirkland,
WA) and grown in Medium 131 containing microvascu-
lar growth supplement (Gibco, Life Technologies Corp.,
Carlsbad, CA), 50U/mL penicillin, and 50 𝜇g/mL strepto-
mycin at 37∘C, 95% air, and 5% CO
2
. For conventional
RT-PCR, RNA extraction was followed by reverse tran-
scription using RevertAid (Fermentas GMBH, St. Leon-
Rot, Germany) and oligo-dT primers. cDNA was amplified
(HotStarTaq Master Mix Kit, Qiagen) using NFAT isoform
specific primers as previously described [7]. PCR products
were separated by agarose gel electrophoresis and confirmed
by sequencing. Equal amounts of RNA for whole retina
and isolated retinal vessel preparations were used for the
reverse transcription reactions. For quantitative real time
PCR, cDNAwas synthesized using random hexamer primers
and amplified on a 7900HT TaqMan system (Applied Biosys-
tems, Carlsbad, CA) using TaqMan Gene Expression assays
for Tau (Mm00521988 m1), GFAP (Mm01253033 m1), OPN
(Mm00436767 m1), ICAM-1 (Mm00516023 m1) with 18S
(Hs999999021 s1), HPRT (Mm00446968 m1), Cyclophilin B
(Mm00478295 m), and GAPDH (4352339E) as endogenous
controls. Relative quantities of target genes were calculated
using the comparative threshold method (ΔΔC
𝑡
) and experi-
ments were performed in triplicate.
2.4. Intraperitoneal Glucose Tolerance Test (IP-GTT). BALB/c
mice fasted for 16 hours followed by i.p. injection of glucose
(2 g/kg body weight) or saline (vehicle). Blood glucose was
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measured in whole venous blood from the tail vein (One-
Touch glucometer, LifeScan, Inc., CA). Mice were euthanized
30minutes or 6 hours after the glucose bolus, after which eyes
were enucleated and retinas were dissected free and used for
measurements of NFATc3 nuclear accumulation by confocal
immunofluorescence microscopy or for measurements of
luciferase activity as explained below, respectively.
2.5. Streptozotocin (STZ) Treatment. Mice were injected i.p.
with STZ (60mg/kg body weight in citrate buffer, pH 4.5)
or vehicle (citrate buffer), once a day during 4 or 6 days, for
NFAT-luc and BALB/c, respectively, as previously described
[3]. Mice were weighed and glucose levels measured at
various time points. NFAT-luc mice (control, diabetic, and
diabetic treated with the NFAT blocker A-285222) were
euthanized at different time points as specified in the results.
BALB/cmice (control and diabetic with or without A-285222,
resp.) were euthanized 4 weeks after the first STZ/vehicle
injections.
2.6. Confocal Immunofluorescence. For measurements of
NFATc3 nuclear accumulation, retinas and cerebral arteries
from BALB/c mice were dissected in ice-cold Ca2+-free PSS
and treated ex vivo as described in Results section. Alterna-
tively, retinas were fixed directly after IP-GTT. Whole retinas
were fixed with Histochoice MB (AMRESCO Inc., Solon,
OH), blocked and permeabilized with 2% BSA containing
0.2% Triton X-100 in PBS for 2 hours, and incubated with
rabbit polyclonal anti-NFATc3 (1 : 100, Santa Cruz Biotech-
nology, Santa Cruz, CA) overnight at 4∘C and with Cy5-anti-
rabbit IgG (1 : 500, Jackson ImmunoResearch, West Grove,
PA) for 2 hours at room temperature. Human umbilical vein
endothelial cells (HUVEC; Gibco, Life Technologies Corp.,
Carlsbad,CA) andHRMVECswere grownon glass coverslips
and stained with goat polyclonal anti-NFATc2 (Santa Cruz
Biotechnology, Santa Cruz, CA) and with Cy5-anti-goat IgG
(1 : 500, Jackson ImmunoResearch, West Grove, PA). Nuclei
were stained with SYTOX Green. Cerebral arteries were
processed as previously described [2, 3]. NFATc3 or NFATc2
and nuclear regions were detected by monitoring Cy5 and
green fluorescence, respectively, on a Zeiss LSM 5 laser
scanning confocal microscope. Images were obtained at 63x
magnification and mean fluorescence intensity of nuclear
NFATc3 or NFATc2 was quantified using the Zeiss LSM 5
analysis software as previously described [3, 7]. Orientation
of the nuclei was used to distinguish endothelial from smooth
muscle cells. For visualization of colocalized image regions
or double tagged regions (red: NFATc3 tagged with Cy5
and green: nuclear regions tagged with SYTOX Green), the
crosshair function of the LSM program was used. This tool
leads to the distribution of all image pixels over 4 quadrants
in a scattergram according to their intensity levels, with the
background pixels sorted into the bottom left quadrant, the
single-tagged pixels (either red or green) into the upper
left and bottom right quadrants, and the pixels having
an intensity above the background in both channels (i.e.,
colocalized pixels) represented by the upper right quadrant.
The image pixels corresponding to the upper right quadrant
are then color-coded white in the original image to allow fast
identification of colocalized areas. Also, staining of retinal
whole-mounts with antibodies against vonWillebrand factor
(1 : 400, DAKO), smooth muscle 𝛼-actin (1 : 400, Sigma), and
platelet-derived growth factor 𝛽-receptor (PDGFR𝛽, 1 : 100,
Santa Cruz) was performed to identify endothelial, smooth
muscle cells and pericytes, respectively (see Supplementary
Figure 1 in the Supplementary Material available online
at http://dx.doi.org/10.1155/2015/428473). For quantification,
multiple fields for each retina, vessels, or coverslips were
imaged and analyzed under blind conditions.
2.7. Luciferase Reporter Assay. Luciferase activity was mea-
sured in intact retinas and in isolated retinal vessels as
previously described [2, 7]; optical density was measured
using a Tecan Infinite M200 instrument (Tecan Nordic AB,
Mo¨lndal, Sweden) and data was expressed as relative light
units per microgram protein.
2.8. Cytokines in Plasma and Retina Homogenates. Cytokine
concentrations were measured in plasma and retina
homogenates using an inflammation 7-Plex kit (Meso Scale
Discovery, Rockville, MD). The lower detection limits were
within the range specified by the manufacturer. Plasma
OPN was assayed using Quantikine Mouse OPN ELISA kit
(R&D Systems, Abingdon, UK). Absorbance was measured
at 450 nm and the lower limit of detection was 5.7 pg/mL.
Plasma from OPN−/− mice [22] (kindly provided by Anna
Hultga˚rdh, Lund University) was used as negative control.
2.9. Quantitative Assessment of Blood-Retinal Barrier Per-
meability. FITC-labelled albumin (45mg/kg; Sigma) was
administered i.v. and 1 hour later, mice were anesthetized,
and a blood sample was collected from the left ventricle. Mice
were perfused with PBS and euthanized by cardiac puncture.
The fluorescence of retinal extracts and a 1 : 1000 dilution
of plasma were measured at 485 nm (Ex) and 515 nm (Em).
The concentration of FITC-albumin was calculated from a
standard curve of FITC-labelled albumin in PBS and the
blood-retinal barrier permeability was calculated as follows
and was expressed as (𝜇L/mg∗hr/eye):
FITC − albumin retina (mg) /Retina dry weight (mg)
[FITC − albumin] (mg) /Plasma (ul) × Circulation time (h)
.
(1)
2.10. Statistics. Results are expressed as means ± SEM unless
otherwise specified. Statistical analysis was performed using
GraphPad software (Prism 5.01). The use of parametric or
nonparametric tests was based on results from analyses of
distributions. Statistical significance was determined using
Student’s 𝑡-test; Kruskal-Wallis followed by Dunn’s multiple
comparison test for nonparametric data; or one- or two-
way ANOVA as stated in the figure legends, followed by
Bonferroni post hoc tests (∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 <
0.001). Pearson’s test was used for correlation analyses.
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Figure 1: Expression of NFATc transcription factor genes in whole retina and in retinal microvessels. (a) RT-PCR analysis of NFAT isoform
(c1–c4) expression in whole retinas and isolated retinal vessels from nondiabetic FVBN mice (𝑁 = 8). ((b)-(c)) All NFAT family members
are expressed in mouse aorta (b) and in cultured human retinal microvascular endothelial cells (HRMVECs, (c)). Markers (M) for 300, 500,
and 700 bp are indicated. (d)(i) Dark field/side illumination of a vascular network isolated from whole retina as described in material and
methods (Section 2.2). (d)(ii) Confocal image showing smooth muscle 𝛼-actin positive staining (red) and nuclei (green) of an isolated retinal
vessel preparation. Note the lack of surrounding nonvascular tissue (black background). (d)(iii) Confocal image of a smaller caliber vessel
network stained as in (d)(ii) showing the absence of smooth muscle 𝛼-actin positive cells. Scale bars = 500𝜇m for (d)(i); 20𝜇m for (d)(ii)-
(d)(iii). (e)-(f) Quantitative RT-PCR data showing expression levels of neuronal maker Tau (e) and glial marker GFAP (f) in whole retina and
in isolated retinal vessels, both normalized to 18S.𝑁 = 6 retinas/group.
3. Results
3.1. Expression of NFATc Transcription Factors in Mouse
Retina. RT-PCR was used to examine the expression of
NFATc transcription factors in mouse retina. NFATc2 and
NFATc3 were readily detected in whole retina from mouse,
whereas expression of NFATc1 was very low and of NFATc4
very low to undetectable (Figure 1(a)). Using the same primer
pairs as for retina, all four NFAT family members were
detected in intact mouse aorta (Figure 1(b)) and in cultured
human retinal microvascular endothelial cells (HRMVECs;
Figure 1(c)). In intact mouse retinal vessels (Figure 1(d)),
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virtually devoid of neuronal and glial cells (Figures 1(e)-
1(f)), both NFATc2 and NFATc3 were detected (Figure 1(a)).
Although the level of expression is not a determinant of
transcription factor activity, we chose to focus on NFATc3,
given that we previously established that this family member
is glucose sensitive and activated in aorta and cerebral arteries
in diabetic mice [2, 3, 9].
3.2. Acute Hyperglycemia Increases NFATc3 Nuclear Accu-
mulation and NFAT-Dependent Transcriptional Activity in
Retinal Microvessels. Raising the extracellular glucose con-
centration ex vivo from 2mmol/L to 20mmol/L for 30min
significantly increased NFATc3 nuclear accumulation in the
endothelium of retinal vessels (Figures 2(a)-2(b)). Exposure
to high glucose results in a 115% increase in mean fluo-
rescence intensity of nuclear NFATc3 when compared to
vessels incubated under low glucose conditions (Figure 2(c)).
This increase was prevented by the NFAT blocker A-285222
(1 𝜇mol) and also by the ectonucleotidase apyrase (3.6U/mL),
implicating extracellular nucleotides in the activation of
NFATc3 (Supplementary Figures 2(a)-2(b)). Mannitol and L-
glucose failed to induceNFATc3 nuclear accumulation, ruling
out a possible osmotic effect of glucose and indicating that
glucose needs to be metabolized in order to activate NFAT
signaling (Supplementary Figures 2(c)-2(d)). For compar-
ison, in Figure 2(d), a less dramatic NFATc3 activation is
observed in the endothelium ofmouse intact cerebral arteries
after 30min stimulation with HG, which was prevented by
the NFAT blocker.
We have not been able to perform a quantitative analysis
ofNFATc2 activation in retinalwhole-mounts due to substan-
tial nonspecific binding of the antibodies tested, resulting in
less reliable immunostaining. However, using HUVEC and
HRMVECs, we have not seen any significant effect of glucose
on NFATc2 nuclear accumulation (Supplementary Figure 3).
To test the effect of acute hyperglycemia on NFATc3
activation in vivo, i.p. glucose tolerance tests (IP-GTT)
were performed and NFATc3 nuclear accumulation was
determined in retinal vessels by confocal microscopy. Blood
glucose levels were significantly higher in mice after the IP-
GTT (Figure 3(a)), and this was accompanied by a 110%
increase in mean fluorescence intensity of nuclear NFATc3 in
the endothelium of mouse retinal microvessels (Figure 3(b))
compared to vehicle-injected mice. Levels of NFATc3 nuclear
accumulation correlated with blood glucose concentrations
(𝑟 = 0.600; 𝑃 = 0.017). Nuclear accumulation of NFAT trans-
lated into increasedNFAT-dependent transcriptional activity,
as evidenced by significantly increased luciferase activity
in isolated retinal vessels of transgenic NFAT-luc reporter
mice after an IP-GTT (Figures 3(c)-3(d)). Interestingly, we
could not detect any effect of acute hyperglycemia on NFAT-
dependent transcriptional activity when measured in whole
retina (Figure 3(e)), suggesting selective glucose-dependent
activation of NFAT in the vascular retina.
3.3. Chronic Hyperglycemia Increases NFAT-Dependent Tran-
scriptional Activity in Retinal Vessels in Two Different Models
of Diabetes. NFAT-lucmicewere injectedwith STZor vehicle
Table 1: A-285222 treatment does not affect plasma cytokine levels
in diabetic NFAT-luc mice.
Cytokine
(pg/mL)
Control
(𝑁 = 10)
STZ
(𝑁 = 13)
STZ + A-285222
(𝑁 = 8)
IL-10 22.0 ± 3.6 28.1 ± 7.0 29.4 ± 21.1
TNF-𝛼 0.7 ± 0.3 0.6 ± 0.5 0.2 ± 0.5
IFN-𝛾 1.3 ± 1.3 1.2 ± 0.5 1.4 ± 0.8
IL-12p70 3.9 ± 5.5 8.2 ± 9.0 32.7 ± 56.2
IL-1𝛽 1.0 ± 0.4 1.2 ± 0.5 1.1 ± 0.8
IL-6 13.3 ± 5.7 16.6 ± 5.8 25.0 ± 22.4
KC 51.4 ± 27.5 56.5 ± 17.7 64.1 ± 53.6
Data expressed as mean ± SD. Plasma cytokine levels (pg/mL) in control and
STZ-treated NFAT-luc mice that had been treated with the NFAT inhibitor
A-285222 (0.15mg/kg/day) or saline, measured 2 weeks after the first
STZ/vehicle injection. One-way ANOVA revealed no significant differences
between groups. Interleukin- (IL-) 10, tumor necrosis factor- (TNF-) 𝛼,
interferon- (IFN-) 𝛾, IL-12p70, IL-1𝛽, IL-6, and keratinocyte chemoattractant
(KC) were measured using multiplex technology.
once a day for 4 days and euthanized one week after the last
injection (day 12). At this time point, blood glucose levels
were significantly elevated in diabetic mice when compared
to controls (Figure 4(a)). This resulted in a 68% increase in
NFAT-dependent transcriptional activity in isolated retinal
microvessels (Figure 4(b)), which correlated with blood glu-
cose (𝑟 = 0.696,𝑃 = 0.037). NFAT-luciferase activity was also
measured in whole retinas at day 12, but no differences were
observed between diabetic and control mice (Figure 4(c)),
not even at earlier or later time points (days 7 and 16; data
not shown). Akita mice have a single amino acid substitution
in the insulin 2 gene that causes misfolding of the insulin
protein, progressive loss of 𝛽-cell function, and significant
hyperglycemia as early as 4-5 weeks of age [23]. In our hands,
at 6 weeks of age Akita/NFAT-luc mice had significantly
increased blood glucose levels compared to WT/NFAT-luc
mice (Figure 4(d)) and this was accompanied by a 148%
increase in luciferase activity in isolated retinal microvessels
(Figure 4(e)). Together, these results demonstrate activation
of NFAT signaling in retinal vessels in two different models
of type 1 diabetes.
3.4. Effect of NFAT-Signaling Inhibition on Inflammatory
Cytokines and Endothelial Activation. Nondiabetic (control)
and STZ-induced diabetic NFAT-luc mice received daily i.p.
injections of the NFAT blocker A-285222 (0.15mg/kg body
weight) or vehicle and were euthanized 16 days after the
first injections. Diabetes resulted in significantly reduced
levels of the anti-inflammatory cytokine IL-10 inwhole-retina
homogenates, whichwere completely restored inmice treated
withA-285222 (Figure 5(a)). Blood glucose levels were signif-
icantly higher in STZ-treatedmice when compared to control
mice (Figure 5(b)) but were not affected by treatment with
A-285222 (Figure 5(b)). The levels of other cytokines such
as IFN-𝛾, IL-12p70, IL-1𝛽, IL-6, GRO𝛼/keratinocyte-derived
chemokine (KC), and TNF𝛼 in whole-retina homogenates
were not significantly affected by diabetes or treatment with
A-285222 (Figures 5(c)–5(h)).When the same cytokines were
examined in plasma, no differences were detected between
diabetic mice treated with or without A-285222 (Table 1),
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Figure 2: High glucose activates NFATc3 in the endothelium of retinal vessels. (a) Representative confocal immunofluorescence images
of retinal whole-mounts, stimulated for 30min in low (LG; 2mmol/L; left panels) or high (HG; 20mmol/L; right panels) extracellular
glucose and stained for NFATc3 (red) and SYTOX green for identification of nuclei (green). Merged and individual channel images are
shown. Endothelial cells were identified by the orientation of their nuclei. (b) Higher magnification confocal images of retinal whole-
mounts stimulated and stained as in ((a), upper panels) and pseudocolored images to visualize colocalization of NFATc3 and SYTOX green
(white; lower panels). Scale bars = 50𝜇m. (c) Summarized mean fluorescence intensity data from experiments as in (a), showing NFATc3
nuclear accumulation after 30min stimulation in LG or HG in the presence or absence of A-285222 (1 𝜇mol), or apyrase (3.6U/mL), or after
stimulation with LG plus mannitol (18mmol/L), or LG plus L-glucose (18mmol/L).𝑁 = 21 and 22 retinas for LG and HG, respectively; 5–7
retinas for the other stimulatory conditions. ∗∗∗𝑃 < 0.001 versus all other groups. (d) Summarized mean fluorescence intensity data showing
NFATc3 nuclear accumulation in mouse cerebral arteries after 30min stimulation in LG or HG in the presence or absence of A-285222
(1 𝜇mol).𝑁 = 5/group. ∗𝑃 < 0.05 versus LG.
suggesting that the effect on retinal IL-10 is local, rather than
systemic.
In a separate set of experiments using BALB/c mice
and contrary to expectations, one month after the first
STZ injection we did not detect enhanced OPN or ICAM-1
mRNA in the retinal vessels of diabetic mice (Figures 6(a)-
6(b)). OPN levels in the aortas of these same diabetic mice
were elevated when compared to controls [3], suggesting
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Figure 3: Acute hyperglycemia increases NFATc3 nuclear accumulation andNFAT-dependent transcriptional activity in retinal microvessels.
(a) Blood glucose levels measured before and 30min after an i.p. injection of glucose (2 g/kg; IP-GTT, black bars) or saline (control, white
bars) in BALB/c mice, 𝑁 = 7-8 mice/group. (b) Summarized data from confocal immunofluorescence experiments in the mice described
in (a), showing increased NFATc3 nuclear accumulation in the retinal endothelium of hyperglycemic mice when compared to controls. (c)
Blood glucose levels measured before and 30min after an i.p. injection of glucose (2 g/kg; IP-GTT, black bars) or saline (control, white bars)
NFAT-luc mice. (d)-(e) NFAT-dependent transcriptional activity in isolated retinal vessels (d) and whole retinas (e) in the NFAT-luc mice
described in (c) measured 6 hours after i.p. injection of glucose or saline. Relative light units (RLU) in (d) and (e) were normalized to protein
content and expressed as percentage of vehicle-treated control. 𝑁 = 7–12 mice/group. ∗𝑃 < 0.05 and ∗∗∗𝑃 < 0.001 versus normoglycemic
control group.
differential regulation of OPN expression depending on the
vascular bed. Similar to what we observed in retinal vessels
from BALB/c mice, neither OPN mRNA in retinal vessels
(Supplementary Figure 4(a)) nor OPN protein levels in
whole-retina homogenates (data not shown) were changed
in NFAT-luc mice after 2 weeks of diabetes. Furthermore,
OPN mRNA in retinal vessels of Akita mice was not
changed (Supplementary Figure 4(b)). STZ-induced diabetes
in hyperlipidemic Apoe−/− mice, on the other hand, resulted
in a 2.1-fold increase in OPN mRNA in retinal vessels, 8
weeks after the first STZ injection (Supplementary Figure
4(c)), highlighting potential differences in the regulation of
OPN depending on mice strain, duration of diabetes, and/or
blood lipid levels. Despite the lack of diabetes-induced OPN
and ICAM-1 expression in BALB/cmice, daily injections with
A-285222 lowered the levels of OPN and ICAM-1 mRNA
(Figures 6(a)-6(b)). No changes in plasma levels of OPN, IL-
10, TNF𝛼, IL-12p70, IL-1𝛽, IL-6, and KC were observed in
response to diabetes or NFAT inhibition; however plasma
IFN-𝛾 was reduced in diabetic animals that had been treated
with A-285222 (Supplementary Table S1).
3.5. In Vivo Inhibition of NFAT Reduces Diabetes-Induced
Vascular Permeability. Vascular permeability was measured
in the retinas of 8-week-old Akita and WT mice that
had been treated with i.p. injections of A-285222 or saline
(control) for 2 weeks. Mean blood glucose was 10.0mmol/L
and 18.5mmol/L for control and Akita mice, respectively.
Vascular permeability was increased 2.1-fold in diabetic
versus control mice (Figure 7). Inhibition of NFAT signaling
with A-285222 completely abrogated the diabetes-induced
permeability (Figure 7).
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Figure 4: Chronic hyperglycemia increases NFAT-dependent transcriptional activity in retinal vessels from two different mouse models of
diabetes. (a) Blood glucose levels in NFAT-luc mice, treated with STZ (60mg/kg; black bars) or vehicle (citrate buffer; white bars), measured
12 days after the first injection. (b) NFAT-dependent transcriptional activity (RLU𝜇g−1) in isolated retinal vessels (𝑁 = 6-7mice/group) and
(c) in whole retinas (𝑁 = 4–7) from the mice in (a). Data is expressed as percentage of activity in normoglycemic control mice. (d) Blood
glucose levels inAkita/NFAT-lucmice (black bars) andWT/NFAT-lucmice (white bars) at 6weeks of age. (e)NFAT-dependent transcriptional
activity (RLU𝜇g−1) in isolated retinal vessels from the same mice as in (d). Data is expressed as percentage of activity in WT control mice.
𝑁 = 11–15mice/group. ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; and ∗∗∗𝑃 < 0.001 versus corresponding normoglycemic control groups.
4. Discussion
In this study we show that mouse retinal vessels express
NFATc3 and that this transcription factor is sensitive to
changes in extracellular glucose levels. In two mouse models
of diabetes, STZ-induced, and Akita mice, diabetes results in
increased NFAT-dependent transcriptional activity in retinal
vessels. Interestingly, levels of the potent anti-inflammatory
cytokine IL-10 were decreased in the retina of diabetic mice
and these were restored by treatment with the NFAT blocker
A-285222 for 2 weeks. The effects on retinal IL-10 were
achievedwithout any impact on blood glucose or on the levels
of circulating plasma cytokines (IL-10, IFN-𝛾, IL-12p70, IL-
1𝛽, IL-6, KC, and TNF𝛼). Moreover, inhibition of NFAT for
4 weeks resulted in decreased expression of basal OPN and
ICAM-1mRNA levels in retinal vessels. We also demonstrate
that inhibition of NFAT abrogates the increased vascular
permeability observed in diabetic Akita mice. Therefore, we
suggest that NFAT inhibition may exert a protective effect in
the retina of diabetic mice.
The pattern of expression of NFATc transcription factors
seems to vary depending on the vascular bed, with arteries
such as the aorta that express all NFATc family members
(Figure 1(c)), myometrial arteries expressing NFATc1,
NFATc3, and NFATc4 [7], or cerebral arteries which express
NFATc3 and NFATc4 [24]. NFAT transcription factors
were initially considered to have redundant functions, but
differential activation of NFAT proteins within a cell [25]
and varied expression profiles among cell types have been
observed, suggesting functions specific to the different NFAT
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homogenates from NFAT-luc mice, treated with STZ (60mg/kg) or vehicle (citrate buffer). Mice received daily i.p. injections of A-285222
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IFN-𝛾, IL-12p70, IL-1𝛽, IL-6, and KC levels were determined in whole-retina homogenates from the same mice as in (a). Cytokines levels
were normalized to protein content and are expressed as percentage of control. No significant differences were observed between the groups.
family members. In the intact mouse retina, all four isoforms
could be detected, whereas in isolated retinal vessels only
NFATc2 and NFATc3 were demonstrated. This suggests that
NFATc1 and NFATc4 may be of neuronal origin [26, 27] or
may be upregulated in culture, given that primary retinal
endothelial cells expressed all four isoforms. Our previous
work in conduit and resistance arteries focused on the effects
of glucose on NFATc3 in vascular smooth muscle cells [2],
but here we show that endothelial NFATc3 seems to be
sensitive to changes in extracellular glucose as well. NFATc2,
on the other hand, did not seem sensitive to glucose, at least
in cells (Supplementary Figure 2).
Diabetes is characterized by both sustained hyper-
glycemia and acute glucose fluctuations. There is cogent evi-
dence for the deleterious effects of sustained hyperglycemia,
but the role of glucose variability is less well documented
10 Journal of Diabetes Research
(a) (b)
O
PN 0.5
0
1
*
STZ
Control
∗
Control + A-285222
STZ + A-285222
0.1
0
0.3
0.2
IC
AM
-1
∗
Figure 6: In vivo inhibition of NFAT reduces the expression of OPN and ICAM-1 in retinal vessels. mRNA expression of (a) OPN and
(b) ICAM-1 in isolated retinal vessels from BALB/c mice treated with STZ (60mg/kg) or vehicle (citrate buffer). Mice received for 4 weeks
daily i.p. injections of A-285222 (0.29mg/kg for 2 weeks followed by 0.15mg/kg until termination) or vehicle (saline). Expression levels were
determined by quantitative RT-PCR andHPRT was used as endogenous control.𝑁 = 7-8mice/group. Two-wayANOVArevealed a significant
effect of A-285222 on OPN and ICAM-1 expression; ∗𝑃 < 0.05.
100
0
150
50
Akita
Control Control + A-285222
Akita + A-285222
#
∗
Pe
rm
ea
bi
lit
y 
(𝜇
L/
m
g∗
hr
/e
ye
)
Figure 7: In vivo inhibition of NFAT reduces diabetes-induced
vascular permeability. Vascular permeability (𝜇L/mg∗hr/eye) in the
retinas of 8-week-oldAkitamice andWTmice that had been treated
for 2 weeks with daily i.p. injections of A-285222 (0.29mg/kg) or
saline (control). 𝑁 = 8, 10, 7, and 7 for WT, Akita, WT + A-
285222, and Akita + A-285222, respectively. Two-way ANOVA with
Bonferroni post hoc test revealed ∗𝑃 < 0.05 versus WT and ##𝑃 <
0.05 versus Akita.
[28]. To our knowledge, nothing is known regarding the effect
of glycemic peaks and nadirs on transcriptional activity in
intact arteries. In mice, blood glucose reaches a maximum
value upon a single IP-GTT after 30 minutes and returns
to control levels after 120 minutes [29]. The results from
this study show that acute elevations in blood glucose, as
those induced by IP-GTT, efficiently induced NFAT nuclear
accumulation and NFAT-dependent transcriptional activity
in retinal vessels. Sustained hyperglycemia in STZ-treated
mice resulted in increased NFAT transcriptional activity in
retinal vessels. In contrast, NFAT transcriptional activity
in whole retinas was not changed after an IP-GTT or
after sustained hyperglycemia, suggesting different activation
requirements of NFAT proteins in the nonvascular retina.
Results also emphasize the importance of isolating retinal
vessels rather than using whole-retina preparations for the
study of pathological changes in the microvasculature.
The contribution of different cell types in the retina, as
well as the chronology of events in the pathogenesis of DR,
is still a matter of debate [6, 30, 31]. However, accumulating
evidence suggests that localized inflammatory processes play
a role in the early phases of DR [6], including increased
expression of adhesion molecules, cytokines, and growth
factors. For cytokine level quantificationwe chose amultiplex
assay designed to measure IL-10, IFN-𝛾, IL-12p70, IL-1𝛽,
IL-6, KC, and TNF𝛼. Except for KC, all of these cytokines
have been implicated in the pathogenesis of human diabetic
retinopathy [32–41]. In our study, 2 or 4 weeks of STZ-
induced diabetes had no significant effect on the levels
of circulating cytokines, despite the fact that animals had
significantly higher blood glucose levels. The reason why
this model fails to affect plasma cytokines as it could be
predicted from previous studies may be due to differences
between species. Rodents and in particular mice are known
to be resilient to hyperglycemia-induced changes and only
mimic early stages of diabetic retinopathy [42]. The plasma
cytokine results presented here for FVBN and BALB/c mice
are however in line with previous data obtained in C57BL/6,
where we showed that 8 weeks of STZ-induced diabetes does
not increase the levels of circulating inflammatory cytokines
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[43]. Treatment with A-285222 for 2 weeks had no effect on
plasma cytokine levels, but 4-week treatment significantly
reduced plasma IFN-𝛾 concentration in diabetic animals
(Table S1).
To better resolve potential local changes in cytokine
production in the retina, we measured the same cytokines
in retina homogenates. In the STZ-mouse model of diabetes
that we used here, 2 weeks of diabetes resulted in decreased
levels of IL-10. The same results were obtained after 4 weeks
of diabetes in other strains (FVBN and BALB/c; data not
shown). This cytokine is produced by numerous immune
cells (i.e., T-helper cells, regulatory T cells, B cells,monocytes,
macrophages, and dendritic cells [44]) and plays a central
nonredundant role in limiting inflammation in vivo [45]. Also
local production of endogenous IL-10 has been suggested
to limit angiotensin-II-induced oxidative stress and vascular
dysfunction in mouse carotid arteries [46]. Our results
demonstrate that in vivo treatment for 2 weeks with A-285222
restores IL-10 levels, suggesting that NFAT inhibition may be
protective for the retina. Apart from IL-10, no other changes
in cytokine levels in retina or in the expression of ICAM-
1 mRNA in retinal vessels were observed in response to
diabetes, at least at these early time points and in these mice
strains.This contrasts with previous findings in C57Bl/6mice
at later time points after 8 weeks of diabetes, in which wewere
able to detect increased ICAM-1mRNA in retinal vessels and
enhanced levels of TNF𝛼, IL-6, and IL-1𝛽 mRNA in whole-
retina homogenates [21].
We have recently shown that hyperglycemia induces
the proinflammatory cytokine OPN in mouse aorta by
direct binding of NFATc3 to the OPN promoter [3]. OPN
protein was increased in subvalvular aortic sections and
in plasma of STZ-treated diabetic mice 8 weeks after the
onset of hyperglycemia [3]. OPN has been reported to be
increased in the vitreous of patients with DR compared to
nondiabetic patients [47] and in retinal endothelial cells after
in vitro stimulation with high glucose, resulting in enhanced
endothelial cell migration [48]. However, in the STZ-model
used here, no changes in the expression of OPN in retinal
vessels were observed at early time points, after 2 or 4 weeks
of diabetes. Hyperglycemia inAkitamice also failed to induce
OPN expression. In contrast, a 2.1-fold increase in retinal
microvessel OPN mRNA was observed in hyperlipidemic
Apoe−/− mice at 8 weeks after the first STZ injection, indicat-
ing that diabetes duration or metabolic state is of importance
for regulation of OPN in retinal microvessels. However,
despite the lack of diabetes-induced OPN expression in
BALB/c mice after 4 weeks of diabetes, in agreement with
previous results in larger vessels [3], in vivoNFAT-inhibition
for the duration of the experiment reduced the levels of OPN
mRNA in retinal vessels regardless of the diabetic condition,
indicating a potential NFAT-dependent regulation of OPN
under basal conditions in this tissue. NFAT inhibition
also reduced ICAM-1 mRNA levels in retinal microvessels,
highlighting a potential mechanism by which NFAT inhibi-
tion may prevent leukostasis and inflammation in diabetic
retinopathy.
An early feature of diabetic retinopathy is the breakdown
of the BRBwhich results in vascular leakage and development
of retinal edema. Clinical evidence from fluorescein angiog-
raphy in patient with diabetic retinopathy indicates that the
inner BRB, which is formed by junctions between endothe-
lial cells of the retinal capillaries, is the primary site of
vascular leakage. In agreement with previous studies [49],
we demonstrate that increased vascular leakage is an early
event in Akita mice. The fact that in vivo treatment with A-
285222 for 2 weeks prevented diabetes-induced changes in
retinal permeability suggests NFAT signaling to play a role
in the regulation of the BRB. In diabetes, increased BRB
permeability is associated with reduced expression of tight
junction (claudin-5, ZO-1, and occludin) and adherens (VE-
cadherin) proteins [50]. Interestingly, a high number ofNFAT
consensus binding sites were found in the promoter region of
claudin-5 (26 sites), theoretically making it a possible direct
target of NFAT regulation.
A-285222 is a low molecular weight (416 daltons) organic
compound [51]. Given its lipophilic nature and small size, it
crosses both the plasma membrane and the nuclear envelope
by simple diffusion. We have previously studied the phar-
macokinetics of A-285222 after i.p. administration in mice
using gas chromatography/mass spectroscopy (GC/MS) [9].
A comparison between plasma levels of A-285222 measured
5min after i.p. injection of the drug and after direct injection
into the circulation (intracardiac) showed that levels were
within the same range regardless of administration route,
indicating high bioavailability and confirming transport
across several membranes. Studies in cynomolgus monkeys
also confirm the cell-permeable nature of the compound, as
A-285222 was readily detected in plasma after oral admin-
istration [52]. As a cell-permeable compound A-285222 is
expected to reach the retinal circulation and enter the cells
in the vessel wall. The effects of treatment on vascular
permeability could therefore be due to direct effects of A-
285222 on vascular NFATc3 activation; however, indirect
effects cannot be ruled out.
In conclusion, these results suggest that NFAT acts as
a glucose-sensor in the wall of retinal microvessels, trans-
lating changes in extracellular glucose concentration into
changes in gene expression leading to enhanced inflamma-
tion, endothelial activation, and vascular permeability. Even
though tight blood glucose and blood pressure control are
key in preventing and/or slowing down the development of
diabetic macular edema and retinopathy, these are therapeu-
tic goals difficult to achieve. Standard of care still relies on
laser photocoagulation and intravitreal injections of corti-
costeroids or more recently anti-VEGF but these are invasive
procedures that can have complications [53]. Therefore, new
approaches beyond current standards of diabetes care are
necessary. Here, we have identified the NFAT signaling as a
putative target for treatment of microvascular complications
in diabetes.
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